Figure 1 . Approved ATMPs in the EU from 2012 to 2022. Blue boxes show ATMPs for which the sponsor is either a pharmaceutical company or a private biotech while orange boxes are those that originally come from an academic centre (universities and hospitals) but developed and commercialised by a pharmaceutical company. For example, Kymriah®, was originally developed at the University of Pennsylvania and bought by Novartis who performed all the pharmaceutical development and commercialisation. Filled boxes are ATMPs that are currently authorised by the EMA while empty boxes show withdrawn products. This figure is adapted from the CAT quarterly highlights and approved ATMPs document.
Figure 2. Overview of the lifecycle of an ATMP (key steps of the drug pharmaceutical development). Adapted from the slides of the STARS Pilot III Regulatory Support project. Figure prepared with Biorender®.